Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Medical Devices

Radiology

Clinical Trials

Pharmaceutical

Biotechnology

Tracer Biotechnologies

More Like This

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

DELAYS IN CANCER TESTING ARE IMPACTING PATIENTS’ ACCESS TO TARGETED THERAPIES, NEW STUDY SUGGESTS

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

PR Newswire associated0

Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring

PR Newswire associated0

TrilliumBiO and Oncobit Launch Advanced Uveal Melanoma Monitoring Solution in the U.S.

PR Newswire associated0

Menarini Silicon Biosystems announces publication of the DETECT III trial results highlighting the potential clinical utility of HER2 testing in circulating tumor cells with CELLSEARCH

PR Newswire associated0

Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA

PR Newswire associated0

TrilliumBiO and Oncobit Partner to Bring Novel Uveal Melanoma Monitoring Solution to the U.S.